# Once-Yearly Lenacapavir Phase 1 Trial

**ID:** TRT-005
**Year:** 2025
**Source:** CROI 2025
**Link:** [https://www.gilead.com/news/news-details/2025/first-clinical-data-for-gileads-investigational-once-yearly-lenacapavir-for-hiv-prevention-presented-at-croi-2025-and-published-in-the-lancet](https://www.gilead.com/news/news-details/2025/first-clinical-data-for-gileads-investigational-once-yearly-lenacapavir-for-hiv-prevention-presented-at-croi-2025-and-published-in-the-lancet)

---

## Abstract

Phase 1 data showing once-yearly intramuscular lenacapavir maintains therapeutic levels for 56+ weeks.

---

## Key Concepts

- Primary research focus from 2023-2025 HIV literature
- Relevant to understanding HIV biology, treatment, or prevention
- Contributes to the broader HIV research landscape

---

## Relevance to Project

This paper contributes to the Ternary VAE bioinformatics project by providing context on:
- HIV sequence evolution and variability
- Biological constraints on viral fitness
- Therapeutic targets and resistance mechanisms

---

*Added: 2025-12-24*
